Overview - Investors & Press - T2biosystems
T2Biosystems     Print Page | Close Window

Overview

Corporate Profile

T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, improves patient care and reduces the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems' products include the T2Dx Instrument, T2Candida Panel and T2Bacteria Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including detection of additional species and antibiotic resistance markers of sepsis pathogens and tests for Lyme disease. For more information, please visit www.t2biosystems.com.
Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$8.91
Change (%)0.00 (0.00%)
Volume0
Data as of 06/19/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
06/13/18Late-Breaking Data and Clinician Reviews on Now FDA-cleared T2Bacteria Panel Underscore Sepsis Prevention Opportunities at ASM Microbe 2018
LEXINGTON, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today late-breaker posters and data presented at the American Society for Microbiology (ASM) Microbe conference on June 7-11 that demonstrate the T2Bacteria® Panel’s accuracy and speed, which may enable more rapid treatment of patients with bloodstream infections in order to prevent sepsi... 
Printer Friendly Version
06/06/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., June 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on June 4, 2018 it issued inducement awards to three new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides ... 
Printer Friendly Version
06/05/18T2 Biosystems Announces Closing of Public Offering of Common Stock
LEXINGTON, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced the closing of its underwritten public offering of 7,015,000 shares of common stock, including 915,000 shares of common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $7.50 per share, before underwriting discounts, for gross proceeds of approximately $52.6 million. All of the shares of common stock sold in the o... 
Printer Friendly Version
06/01/18T2 Biosystems to Present at the Jefferies 2018 Global Healthcare Conference
LEXINGTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to present at the Jefferies 2018 Global Healthcare Conference. The conference is being held June 5-8 at the Grand Hyatt Hotel in New York. Mr. McDonough is scheduled to present on Tuesd... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646

Matthew Clawson, W2O Group 
mclawson@w2ogroup.com
(339) 370-8500

Data provided by Nasdaq. Minimum 15 minutes delayed.